IX. Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine
Authors:
- Michael F. JarvisMJMichael F. Jarvis
- George C. WagnerGWGeorge C. Wagner
- 1 January 1985
- journal article
- Published by Elsevier in Life Sciences
- Vol. 36 (3) , 249-254
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitorsNature, 1984
- Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonismNature, 1984
- Pargyline Prevents MPTP-Induced Parkinsonism in PrimatesScience, 1984
- Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidaseBiochemical and Biophysical Research Communications, 1984
- Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog SynthesisScience, 1983
- Characterization of normal and supersensitive dopamine receptors: Effects of ergot drugs and neuropeptidesJournal of Neural Transmission, 1981
- Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamineBrain Research, 1980
- Chronic parkinsonism secondary to intravenous injection of meperidine analoguesPsychiatry Research, 1979
- Depletion of brain noradrenaline and dopamine by 6‐hydroxydopamineBritish Journal of Pharmacology, 1971